trending Market Intelligence /marketintelligence/en/news-insights/trending/hoj7ftuomr-5px84ou_qja2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers' Opdivo wins Chinese regulatory approval to treat lung cancer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Bristol-Myers' Opdivo wins Chinese regulatory approval to treat lung cancer

The China National Drug Administration approved Bristol-Myers Squibb Co.'s Opdivo to treat a certain type of lung cancer.

The Chinese regulator approved Opdivo to treat patients with non-small cell lung cancer, or NSCLC, without EGFR or ALK genomic tumor aberrations, that has locally advanced or has spread in other parts of the body after receiving prior platinum-based chemotherapy.

The approval was backed by the results of the late-stage CheckMate-078 trial in which 90% of the patients were Chinese.

In the trial, Opdivo cut the risk of death by 32% compared to chemotherapy in patients with previously treated NSCLC. The trial was stopped early by the independent data monitoring committee after determining that Opdivo was better than chemotherapy in extending patients' lives.

Bristol said Opdivo is the first and only PD-1 inhibitor as well as immuno-oncology agent approved in China.